Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.

Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisanò CA, Caccia C, Mellone M, Melloni E, Padoani G, Sosti V, Vailati S, Keywood C.

J Pharmacol Exp Ther. 2018 Dec;367(3):442-451. doi: 10.1124/jpet.118.251645. Epub 2018 Oct 5.

PMID:
30291173
2.

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.

Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C.

J Parkinsons Dis. 2017;7(4):629-634. doi: 10.3233/JPD-171143.

3.

Metabotropic glutamate receptor 5: a target for migraine therapy.

Waung MW, Akerman S, Wakefield M, Keywood C, Goadsby PJ.

Ann Clin Transl Neurol. 2016 Jul 1;3(8):560-71. doi: 10.1002/acn3.302. eCollection 2016 Aug.

4.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

PMID:
27214664
5.

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.

Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.

Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.

6.

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.

Bezard E, Pioli EY, Li Q, Girard F, Mutel V, Keywood C, Tison F, Rascol O, Poli SM.

Mov Disord. 2014 Jul;29(8):1074-9. doi: 10.1002/mds.25920. Epub 2014 May 27.

PMID:
24865335
7.

Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease.

Zerbib F, Bruley des Varannes S, Roman S, Tutuian R, Galmiche JP, Mion F, Tack J, Malfertheiner P, Keywood C.

Aliment Pharmacol Ther. 2011 Apr;33(8):911-21. doi: 10.1111/j.1365-2036.2011.04596.x. Epub 2011 Feb 14.

8.

Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects.

Zerbib F, Keywood C, Strabach G.

Neurogastroenterol Motil. 2010 Aug;22(8):859-65, e231. doi: 10.1111/j.1365-2982.2010.01484.x. Epub 2010 Mar 16.

PMID:
20236248
10.

Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study.

Spierings EL, Keywood C.

Pain Med. 2009 May-Jun;10(4):633-8. doi: 10.1111/j.1526-4637.2009.00618.x. Epub 2009 Apr 22.

PMID:
19453958
11.

Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation.

Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P, Callander M, Wylie K, Novak C, Keywood C, Heath P, Wyllie M.

BJU Int. 2007 Feb;99(2):369-75. Epub 2006 Nov 24.

12.
13.

A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.

Silberstein SD, Elkind AH, Schreiber C, Keywood C.

Neurology. 2004 Jul 27;63(2):261-9.

PMID:
15277618
14.

Frovatriptan use in migraineurs with or at high risk of coronary artery disease.

Elkind AH, Satin LZ, Nila A, Keywood C.

Headache. 2004 May;44(5):403-10.

PMID:
15147247
15.

Consequences of transforming measures of efficacy for acute therapies: 5-HT agonists as a worked example.

Fox AW, Keywood C, Sheftell FD, Spierings EL.

Headache. 2004 Jan;44(1):48-52.

PMID:
14979883
16.

Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans.

Géraud G, Keywood C, Senard JM.

Headache. 2003 Apr;43(4):376-88. Review.

PMID:
12656709
17.

Comparison of therapeutic gain with therapeutic ratio for the assessment of selective 5HT(1B/1D) agonist efficacy in migraine.

Fox AW, Keywood C, Sheftell FD, Spierings EL, Winner P.

Headache. 2002 Jul-Aug;42(7):680-8.

PMID:
12482223
18.
19.

Clinical efficacy of frovatriptan: placebo-controlled studies.

Ryan R, Géraud G, Goldstein J, Cady R, Keywood C.

Headache. 2002 Apr;42 Suppl 2:S84-92.

PMID:
12028324
20.

Dose range-finding studies with frovatriptan in the acute treatment of migraine.

Rapoport A, Ryan R, Goldstein J, Keywood C.

Headache. 2002 Apr;42 Suppl 2:S74-83.

PMID:
12028323
21.

Clinical pharmacokinetics of frovatriptan.

Buchan P, Keywood C, Wade A, Ward C.

Headache. 2002 Apr;42 Suppl 2:S54-62.

PMID:
12028321
22.

Frovatriptan for the acute treatment of migraine: a dose-finding study.

Goldstein J, Keywood C; 251/96/14 Study Group.

Headache. 2002 Jan;42(1):41-8.

PMID:
12005274
23.

Need for invasive cardiological assessment and intervention: a ten year review.

MacRae CA, Marber MS, Keywood C, Joy M.

Br Heart J. 1992 Feb;67(2):200-3.

24.

Angiotensin converting enzyme inhibitors and magnesium conservation in patients with congestive cardiac failure.

Stevenson RN, Keywood C, Amadi AA, Davies JR, Patterson DL.

Br Heart J. 1991 Jul;66(1):19-21.

Supplemental Content

Loading ...
Support Center